Author

Yuka Shirakata

SMC Corporation (Japan)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Arvin Cyrus ArmaniD· 1 shared Jacob Paul LalezariiD· 1 shared Melissa PalmeriD· 1 shared Neil E.Buss· 1 shared Taishi HashiguchiiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

5 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Arvin Cyrus ArmanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Leronlimab a humanized anti-CCR5 monoclonal antibody ameliorates hepatic fibrosis in two preclinical fibrosis mouse models

Melissa Palmer, Taishi Hashiguchi, Arvin Cyrus Arman, Yuka Shirakata, Neil E.Buss, Jacob Paul Lalezari

This study evaluates leronlimab's antifibrotic effects in two mouse models of liver fibrosis, showing significant reduction in fibrosis area with 10 mg/kg/week doses.

ASEAN Journal of Psychiatry · Jan 1, 2026Peer-reviewedPharmacology & Toxicology